Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy

Journal of Gastroenterology

Volumn 40, Issue 1, 2005, Pages 70-78

  Yamasaki, Takahiro ^a   Kimura, Teruaki ^a   Kurokawa, Fumie ^a   Aoyama, Kouji ^a   Ishikawa, Tsuyoshi ^a   Tajima, Kunihiko ^a   Yokoyama, Yuichiro ^a   Takami, Taro ^a   Omori, Kaoru ^a   Kawaguchi, Kotaro ^a   Tsuchiya, Masako ^a   Terai, Shuji ^a   Sakaida, Isao ^a   Okita, Kiwamu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Biochemical modulator; Hepatic arterial infusion chemotherapy; Prognostic factor

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; IODINATED POPPYSEED OIL; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ARTERY CATHETERIZATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE REGIMEN; FEMALE; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HEPATIC ARTERY; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; JAPAN; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 20444431241     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1494-7     Document Type: Article

References (39)

1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
2. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for patients with hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998;28: 751-5.
3. Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421-7.
4. Chung YH, Song H, Song BC, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-91.
5. Toyada H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinomas. Oncology 1995;52: 295-9.
6. Ando E, Yamashita F, Tanaka M, Tanigawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997;79: 1890-6.
7. Urabe T, Kaneko S, Matsusuta E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998;55:39-47.
8. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamaka A, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002;94:435-42.
9. O'Connell MJ. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectral cancer. Cancer 1989;63: 1026-30.
10. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7: 1407-17.
11. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:12-20.
12. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Masuhara M, et al. Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 2002;23:7-17.
13. Yamasaki T, Kurokawa F, Takami T, Omori K, Kawaguchi K, Tsuchiya M, et al. Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study: Is a high dose of the biochemical modulator effective? Hepatol Res 2003;27:36-44.
14. Ebara M, Ohoto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 1990;5:616-26.
15. Yamasaki T, Matsuzaki Y, Irie S, Terai S, Yamashita A, Kurokawa F, et al. Percutaneous hot water injection therapy (PHoT) for treatment of hepatocellular carcinoma: A comparison with percutaneous ethanol injection therapy (PEIT). Int Hepatol Commun 1995;3:305-9.
16. Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994;74: 817-25.
17. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer 2001;91:1342-8.
18. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: Treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188: 79-83.
19. Sakurai M, Okamura J, Kuroda C. Transcatheter chemoembolization effective for treating hepatocellular carcinoma: A histopathologic study. Cancer 1984;54:387-92.
20. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer (in Japanese). 4th ed. Tokyo: Kanehara; 2000. p. 19.
21. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-15.
22. Kanematsu M, Hoshi H, Imaeda T, Murakami T, Inaba Y, Yokoyama R, et al. Detection and characterization of hepatic tumors: Value of combined helical CT hepatic arteriography and CT during arterial portography. Am J Roentgenol 1997;168:1193-8.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
24. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
25. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A 1986;83:8923-5.
26. LoRusso P, Pazdur R, Redman BG, Kinzie J, Vaitkevicius V. Low-dose continuous infusion 5-fluorouracil and cisplatin: Phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol 1989;12:486-90.
27. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer 2002;95:588-95.
28. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990;211:277-87.
29. Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 1992;16:112-7.
30. Fujii T, Takayasu K, Muramatsu Y, Moriyama N, Wakao F, Kosuge T, et al. Hepatocellular carcinoma with portal tumor thrombus: Analysis of factors determining prognosis. Jpn J Clin Oncol 1993;23:105-9.
31. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, editor. The liver and portal hypertension. Philadelphia: Saunders; 1964:49-51.
32. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alphafetoprotein levels. Analysis of 606 patients. Cancer 1989;64:1700-7.
33. Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, Hatanaka Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991;6:385-91.
34. Izumi R, Shimizu K, Kiriyama M, Hashimoto T, Urade M, Yagi M, et al. Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival. J Surg Oncol 1992; 49:151-5.
35. Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001;92:126-35.
36. Hanazaki K, Kajikawa S, Koide N, Adachi W, Amano J. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: Univariate and multivariate analysis. Am J Gastroenterol 2001;96:1243-50.
37. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. A prospective analysis of 227 patients. Cancer 2001;91:561-9.
38. Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H. The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer 1998;83:2076-82.
39. Aoyagi Y, Mita Y, Suda T, Kawai K, Kuroiwa T, Igarashi M, et al. The fucosylation index of serum alpha-fetoprotein as a useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatol Res 2002;23: 287-95.